Clinical Laserthermia Systems AB Stock

Equities

CLS B

SE0022049920

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm 11:29:40 2024-04-26 am EDT 5-day change 1st Jan Change
17.18 SEK -6.27% Intraday chart for Clinical Laserthermia Systems AB -8.62% -37.75%
Sales 2023 8.27M 756K Sales 2024 * 39M 3.56M Capitalization 135M 12.33M
Net income 2023 -79M -7.22M Net income 2024 * -54M -4.94M EV / Sales 2023 20.5 x
Net cash position 2023 14.88M 1.36M Net cash position 2024 * 29.7M 2.71M EV / Sales 2024 * 2.7 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 14
Yield 2023 *
-
Yield 2024 *
-
Free-Float 8.01%
More Fundamentals * Assessed data
Dynamic Chart
Clinical Laserthermia Systems AB Presents Initial Data from the Investigator Initiated Trial at Radboud University Medical Center Using the CLS Transberg System CI
Clinical Laserthermia Systems Receives Second Order from the National Institutes of Health Clinical Center in the US for its TRANBERG Thermal Therapy System Accessories CI
Clinical Laserthermia Systems AB Announces Two Patients with Localized Prostate Cancer Have Been Safely Treated with the Tranberg Thermal Therapy System At the San Luigi Gonzaga University Hospital in Turin, Italy CI
Clinical Laserthermia Systems AB's Subsidiary CLS Americas Signs Agreement with ROSE Urology for Treatment of Prostate Cancer Patients with TRANBERG Thermal Therapy System CI
Clinical Laserthermia Systems Names Interim CFO MT
Clinical Laserthermia Systems AB Announces CFO Changes CI
Clinical Laserthermia Systems AB Announces Publication of Preclinical Assessment of A Non-Cooled MR Thermometry-Based Neurosurgical Laser Therapy System CI
Clinical Laserthermia Systems AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Clinical Laserthermia Systems AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Clinical Laserthermia Systems Gains Underwriting Commitments for Warrant Series Exercise MT
Clinical Laserthermia Systems Files Patent Extension, Expansion for Non-cooled Laser Applicators MT
Clinical Laserthermia Systems AB Files A New Patent Application for Expanded and Extended Protection of the Company's Technology for Laser-Based Tissue Ablation Until 2044 CI
Clinical Laserthermia Systems Prices Warrants; Stock Falls MT
Clinical Laserthermia Systems AB Future-Proofs its Core Technology for MRI-Guided Laser Ablation in A New Agreement with Image Guided Therapy SA CI
Clinical Laserthermia Systems Obtains Marketing Approval for Tranberg Thermal Therapy Portfolio in Singapore MT
More news
1 day-6.27%
1 week-8.62%
Current month-0.81%
1 month+4.25%
3 months-28.42%
6 months-31.83%
Current year-37.75%
More quotes
1 week
16.33
Extreme 16.33
21.93
1 month
14.84
Extreme 14.84
22.00
Current year
14.40
Extreme 14.4
37.60
1 year
14.40
Extreme 14.4
246.00
3 years
14.40
Extreme 14.4
1 292.00
5 years
14.40
Extreme 14.4
2 710.00
10 years
14.40
Extreme 14.4
5 180.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Founder 75 06-03-08
Chief Tech/Sci/R&D Officer - 21-12-31
Members of the board TitleAgeSince
Director/Board Member 69 09-12-31
Chairman 74 10-12-31
Founder 75 06-03-08
More insiders
Date Price Change Volume
24-04-26 17.18 -6.27% 30,435
24-04-25 18.33 -4.23% 12,385
24-04-24 19.14 +2.03% 16,670
24-04-23 18.76 +1.30% 15,299
24-04-22 18.52 -1.49% 19,681

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT

More quotes
Clinical Laserthermia Systems AB is a Sweden-based company active in the medical equipment industry. The Company develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). imILT method can be used for all tumors in solid organ and the potential market is considerable. Examples of tumors which are suitable for treatment are those found in liver, breast, lung, prostate, kidney, pancreas and thyroid. Clinical Laserthermia Systems AB's treatment system consists of two main parts: a mobile laser device and a sterile patient unit for single use. The Company's product is intended for medical professionals within surgical oncology or interventional radiology within oncology. In April 2014, the Company announced the establishment of a subsidiary in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise